A drug designed to help people stop smoking may be linked to “serious psychiatric problems.”
The Wall Street Journal has reported that the United States Food and Drug Administration issued a public health advisory Friday saying is “increasingly likely” that Pfizer Inc.’s smoking-cessation drug Chantix may be tied to serious psychiatric symptoms.
Health Canada approved Chantix for sale in Canada in early 2007.
There is no indication if Health Canada will be issuing a similar warning here in Canada.